Global mRNA Cancer Vaccines and Therapeutics Market Size, Status and Forecast 2021-2027

mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.

 

The global mRNA Cancer Vaccines and Therapeutics market size is projected to reach US$ 968.6 million by 2027, from US$ 213.7 million in 2020, at a CAGR of 24.1% during 2021-2027.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global mRNA Cancer Vaccines and Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global mRNA Cancer Vaccines and Therapeutics market in terms of revenue.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global mRNA Cancer Vaccines and Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global mRNA Cancer Vaccines and Therapeutics market.

 

mRNA Cancer Vaccines and Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global mRNA Cancer Vaccines and Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type

• Adeno Carcinomas
• Mucinous Carcinomas
• Adenosquamous Carcinomas

Segment by Application

• Infectious Disease
• Cancer
• Other

BY REGION

• North America
• U.S.
• Canada
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic
• Rest of Europe
• Asia-Pacific
• China
• Japan
• South Korea
• Southeast Asia
• India
• Australia
• Rest of Asia
• Latin America
• Mexico
• Brazil
• Rest of Latin America
• Middle East & Africa
• Turkey
• Saudi Arabia
• UAE
• Rest of MEA

BY COMPANY

• Moderna Therapeutics
• CureVac
• Translate Bio
• BioNTech
• Sangamo Therapeutics
• Argos Therapeutics
• In-Cell-Art
• eTheRNA
• Ethris
• Tiba Biotechnology